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Abstract
Background
Indigenous populations globally are disproportionately affected by chronic hepatitis B virus
(HBV) infection however contemporary sero-prevalence data are often absent. In the Indige-
nous population of the Northern Territory (NT) of Australia the unique C4 sub-genotype of
HBV universally circulates. There are no studies of the sero-prevalence, nor the impact of
the vaccination program (which has a serotype mismatch compared to C4), at a population-
wide level.
Methods
We examined all available HBV serology results obtained from the three main laboratories
serving NT residents between 1991 and 2011. Data were linked with a NT government data-
base to determine Indigenous status and the most recent test results for each individual
were extracted as a cross-sectional database including 88,112 unique individuals. The pri-
mary aim was to obtain a contemporary estimate of HBsAg positivity for the NT by Indige-
nous status.
Results
Based on all tests from 2007–2011 (35,633 individuals), hepatitis B surface antigen
(HBsAg) positivity was 340% (95%CI 319–361), being higher in Indigenous (608%
[565%-653%]) than non-Indigenous (156%[138%-176%]) Australians, p<00001.
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Birth cohort analysis showed HBsAg positivity fell over time for Indigenous people, with
this decrease commencing prior to universal infant vaccination (which commenced in 1990),
with an ongoing but slower rate of decline since 1990, (023% decrease per year versus
017%).
Conclusions
HBsAg positivity is high in the NT, particularly in the Indigenous population. HBsAg positivity
has fallen over time but a substantial part of this decrease is due to factors other than the
universal vaccination program.
Introduction
Indigenous populations worldwide, irrespective of the income level of their country of resi-
dence, are disproportionately affected by chronic hepatitis B virus (HBV) infection [1,2]. Thus
Indigenous populations are heavily burdened with the sequelae of chronic liver disease and
hepatocellular carcinoma [3]. The Indigenous population of the Northern Territory (NT) of
Australia share many demographic features with other Indigenous populations. Indigenous
Australians constitute 30% of the NT population, with many living in remote, isolated commu-
nities that are characterised by poverty and limited access to adequate health care. In the face
of multiple competing health priorities including a growing burden of non-communicable
chronic diseases, robust longitudinal data on HBV prevalence is required to guide the prioriti-
sation of funding and resource allocation for hepatitis B. The World Indigenous Peoples Con-
ference on Viral Hepatitis noted in the “Anwernekenhe consensus statement”[4] in 2014 that
such data to inform action are desperately lacking.
Prevalence estimates for chronic HBV infection for NT Indigenous Australians range from
08% to 133% [5,6]. These estimates are based on either: small community-specific studies,
[5,6] screening of antenatal women, [7,8] or Australia-wide mathematical modelling [9].
There are therefore important knowledge gaps about the epidemiology of chronic HBV infec-
tion in Indigenous Australians, particularly in males, older people and children.
The NT introduced universal infant HBV vaccination for Indigenous children in 1988 and
for all children in 1990 with a catch-up program for those aged 6–16 years in 1998–9. A study
using NT government notification data and midwifery registers showed a decrease in the prev-
alence of chronic HBV infection in females since the introduction of universal vaccination,
but ongoing substantial disparity between Indigenous and non-Indigenous women [10].
We have recently determined that HBV sub genotype C4 (HBV/C4) is the unique preva-
lent HBV strain in Indigenous NT residents. HBV/C4 has genetic markers of an aggressive
phenotype and has a different serotype to the currently used vaccine [11]. In Gambia where a
serotype mismatch has also been identified, protection against HBV infection (defined as
remaining negative to hepatitis B core antibody, anti-HBc) was 67% 15 years after vaccina-
tion, although protection against chronic infection (remaining HBsAg negative) was high at
96.6% [12]. Concerns arising from the findings that fully vaccinated adolescents in an NT
community setting demonstrated serological evidence of both active and past HBV infection,
mean that reliable sero-prevalence data are particularly important in guiding health policy
[6].
This study aimed to use the results of all existing HBV serology tests from NT residents to
provide a low cost, contemporary estimate of chronic HBV infection prevalence in the NT, as
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well as investigating associations with geographical distribution, Indigenous status and age
group.
Methods
This study was a retrospective analysis of all available HBV laboratory test results including:
HBsAg, anti-HBs, and anti-HBc carried out for any reason in the NT between January 1991
and December 2011. The primary aim was to obtain an estimate of the prevalence of HBsAg
positivity for the NT overall by Indigenous status. Secondary aims were to establish the preva-
lence of anti-HBs positivity and anti-HBc positivity, and to evaluate all HBV markers by birth
cohort with reference to key dates in the introduction of universal childhood HBV vaccination
in the NT.
Ethical approval was obtained from the Human Research Ethics Committee of the North-
ern Territory Department of Health and Menzies School of Health Research (HREC-2012-
1745) and the Central Australian Human Research Ethics Committee (HREC-14-244).
Raw data sources
It is known that 979% of all HBV notifications in the NT come from one of three pathology
providers [13]. We therefore approached these laboratories for all HBV test results (positive
and negative) for 1991–2011. Demographic details including surname, forename, birth date,
gender, and community of usual residence were obtained from the pathology providers.
The data were then edited into a uniform format and amalgamated to create a master data-
set where each line of data was given a unique test identification number and represented a
single testing episode on a specific day (this could include more than one test result, e.g.
HBsAg and anti-HBs done on the same blood draw).
Data linkage
Individuals may have had multiple tests both over time and at different locations. Further-
more, testing data did not include Indigenous status. To identify all tests for each person and
to obtain Indigenous status, we linked the testing dataset to the NT Department of Health’s
Client Master Index (CMI). The CMI is a central identification module for the clinical infor-
mation systems of all NT government health services. It includes name, date of birth, sex,
usual place of residence, Indigenous status and a unique client identification number. Audits
of the CMI have documented a high degree of accuracy [14] and it has been used in previous
data linkage projects [10]. Demographic data from the testing dataset were deterministically
matched to the CMI based on 11 combinations of the variables forename, surname, date of
birth and address, to assign a unique person identifier to each testing record and to obtain
Indigenous status for each individual. Between 5% and 50% of the data matched on each of the
11 levels was manually checked for accuracy. These demographic data were then de-identified
and linked (using the unique test identification number) back to the hepatitis B test results.
Data set for analysis
The dataset was then organised to include the most recent available result for each of the fol-
lowing tests: HBsAg, anti-HBs, and anti-HBc for each individual for whom Indigenous status
was available (Fig 1).
We defined chronic HBV infection as any documented HBsAg positive result i.e. we did
not require each individual to have 2 positive HBsAg test results separated by at least 6 months
in time as per the strict definition of chronic hepatitis B. In order to reach this definition we
Chronic hepatitis B in Australia’s northern territory
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conducted a sensitivity analysis using three subsets of the data: (one) the whole dataset from
1991–2011 defining chronic HBV infection as any positive HBsAg result; (two) data from
2007–2011 defining chronic HBV infection as above; and (three) data from 2007–2011
defining chronic HBV infection as two positive HBsAg results at least six months apart. This
was done to assess possible underestimation of chronic HBV infection using the formal defini-
tion and to establish if there were large difference in the results obtained by each method
(S1 Appendix). Guided by the sensitivity analysis we decided to focus on analysis of dataset
two as described above to minimise the biasing factors such as death, loss of HBsAg and move-
ment out of the NT likely to occur more frequently over a 21 year period.
Data were managed and analysed in STATA (Statacorp, College Station, Texas) version 13.
In descriptive analysis, measures of central tendency and dispersion used were: median and
Fig 1. Flow diagram detailing sources of testing data and production of dataset including only the latest set of
results for each individual with all the duplicate tests and individuals removed.
https://doi.org/10.1371/journal.pone.0184082.g001
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inter-quartile range (IQR) for non-normally distributed variables; and mean and standard
deviation (SD) for normally distributed variables. Proportions within categorical groups were
calculated with the denominator as the total number of individuals who had a result available
for that variable, with binomial confidence intervals. Chi squared tests were used to assess dif-
ferences between categorical groups and two-way tests of proportions for differences within
and across categories. Logistic regression was used for multivariable analysis of dichotomous
dependent variables such as HBsAg; post estimation diagnostics included classification statis-
tics and the Pearson Goodness of Fit test. Interrupted time series analysis using regression
with Newey West standard errors was used to analyse HBsAg prevalence before and after the
implementation of universal vaccination in the NT. The Cumby-Huizinga general test for
auto-correlation was applied to the time series analysis to determine the appropriate lag to
account for auto-correlation [15].
Results
The study describes the most recent HBV serology results for 35,633 individuals (14,025 who
identified as Indigenous Australians) who had blood collected in the NT of Australia between
2007 and 2011 inclusive (dataset two as described above). This was 15% of the total NT esti-
mated resident population in 2011 and 20% of the NT Indigenous population [16] (see Table 1
for breakdown by age, sex and Indigenous status).
The majority of individuals (821%) were aged between 20 and 59 years at the time of test-
ing. The median age of those tested was 32 years (IQR 25–44), with Indigenous people younger
than non-Indigenous (Table 2). Females accounted for 578% of those tested and 394% of all
Table 1. Numbers of people who had one or more hepatitis B serology markers tested between 2007 and 2011 inclusive and the proportion of the
NT population they represent detailed by Indigenous status and age group at the time of testing.
Age
group
Indigenous Non-Indigenous
Male Female Male Female
tested ERP Proportion of
ERP tested (%)
tested ERP Proportion of
ERP tested (%)
tested ERP Proportion of
ERP tested (%)
tested ERP Proportion of
ERP tested (%)
Under 10
years
78 7924 10 71 7326 10 82 10678 08 75 10139 07
10–19
years
996 7290 137 1542 6829 226 493 9973 49 863 8571 101
20–29
years
1880 6452 291 2233 6423 348 1994 15562 128 4867 12871 378
30–39
years
1451 4869 298 1400 5015 281 2195 14422 152 4146 13108 316
40–49
years
1110 3873 287 1105 4135 267 1723 13581 127 1513 12104 125
50–59
years
605 2498 242 715 2602 275 1209 11989 101 1077 10500 103
60–69
years
270 1079 250 312 1279 244 592 7596 78 385 5515 70
Over 70
years
104 494 211 146 762 192 210 3203 66 150 2630 57
Overall 6494 34479 18.8 7524 34371 21.2 8498 87004 9.8 13076 75438 17.3
ERP = Estimated Resident Population from the ABS 2011 census data (16) 41 of 35633 individuals not included in this table as they either had DOB or sex
missing
https://doi.org/10.1371/journal.pone.0184082.t001
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individuals tested were Indigenous. HBsAg, anti-HBc and anti-HBs positivity by Indigenous
status and sex are presented in Table 2.
Odds ratios for HBsAg positivity were 4.08 (95% CI 3.54–4.71 P<0.0001) for Indigenous
Australians versus non-Indigenous Australians, 1.53 (95% CI 1.42–1.66 P<0.001) for male ver-
sus female sex and 1.93 (95% CI 1.78–2.10 P<0.001) for living remotely versus in an urban
centre.
Birth cohort analysis
For Indigenous people, HBsAg positivity was much higher in early cohorts but decreased
steadily with later birth periods to be similar to that of non-Indigenous people in the most
recent cohorts (Fig 2A). For non-Indigenous people HBsAg positivity was around two percent
for most birth cohorts, but increased after 1990 (Fig 2A).
Anti-HBc positivity was substantially higher for Indigenous than non-Indigenous people
until the birth cohorts of individuals born after 1990, in which there was no difference
(Fig 2B).
Anti-HBs positivity was also higher in Indigenous than non-Indigenous cohorts born
between 1930 and 1979 (Fig 2C).
The trends of change in HBsAg, anti-HBc and anti-HBc was similar for males and females
in the Indigenous and non-Indigenous populations (S2 Appendix).
Interrupted time series analysis examining HBsAg positivity by birth cohort found that,
for Indigenous people, the rate of decrease in positivity rates was not greater after the introduc-
tion of the universal vaccine than before (Fig 3A). In the non-Indigenous group there was an
increase in HBsAg positivity rates post 1990 (Fig 3B).
Table 2. Demographics characteristics and HBsAg, anti-HBc and anti-HBs positive results, NT residents tested for HBV in 2007–2011, by Indige-
nous status and sex.
Indigenous Non-Indigenous P value
Number tested1 14,025 21,608
Age (years) median (IQR) 308 (215–433) 33.2 (263–440) <0001
Female n(%) 7531 (537) 7174 (605) <0001
HBsAg
Number tested 11,730 17,123
Proportion positive n(%) 713 (608) 267 (156) <0001
Males n(%) 431 (827) 137 (222) <0001
Females n(%) 281 (431) 129 (118) <0001
Anti-HBc
Number tested 11,966 11,345
Proportion positive n(%) 4583 (383) 1327 (117) <0001
Males n(%) 2541 (436) 759 (145) <0001
Females n(%) 1961 (330) 561 (92) <0001
Anti-HBs
Number tested 10,037 10,403
Proportion positive n(%) 6092 (607) 5763 (554) <0001
Males n(%) 3172 (621) 2474 (521) <0001
Females n(%) 2916 (592) 3279 (582) 0280
1. Any test.
* Sex is missing for two HBsAg positive individuals, one Indigenous and one non-Indigenous.
https://doi.org/10.1371/journal.pone.0184082.t002
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Fig 2. Graphs showing the prevalence (with 95% CI) of HBsAg (A), anti-HBc (B) and anti-HBs (C) by
birth cohort for Indigenous and non-Indigenous people in the Northern Territory.
https://doi.org/10.1371/journal.pone.0184082.g002
Chronic hepatitis B in Australia’s northern territory
PLOS ONE | https://doi.org/10.1371/journal.pone.0184082 September 8, 2017 7 / 13
Fig 3. Interrupted time series analysis looking at HBsAg prevalence trends for (A) Indigenous, (B)
non-Indigenous and (C) total population pre and post 1990 by birth cohort.
https://doi.org/10.1371/journal.pone.0184082.g003
Chronic hepatitis B in Australia’s northern territory
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Only 9.7% of those tested for any HBV marker between 2007 and 2011 were born in the
universal vaccine era (post 1990). Of those born post 1990, HBsAg positivity was 189% (139–
251) overall. Although it appears that in the post 1990 data there is a continued decrease in
HBsAg positivity for Indigenous people and an increase in HBsAg positivity for non-Indige-
nous people (Fig 3A and 3B) the confidence intervals, particularly for the non-Indigenous
group, are wide and overlapping.
Discussion
This cross-sectional analysis of a large NT-wide HBV serology dataset documents a high con-
temporary prevalence of HBsAg positivity of 34% among people referred for HBV testing in
the NT of Australia. HBsAg positivity was significantly higher in Indigenous Australians
(608%) compared to their non-Indigenous counterparts (156%) and also in men (499%)
compared to women (235%). These overall figures are higher than other recent Australian
estimates of chronic HBV infection prevalence. The most recent Australian sero-survey docu-
ments an Australia-wide chronic HBV infection prevalence of 08% [17] and the National Aus-
tralian Hepatitis B Mapping Project an Australia-wide chronic HBV infection prevalence of
102% and an NT prevalence of 168% [9]. A recent meta-analysis reported a chronic HBV
infection prevalence in Indigenous Australians of 396% in those studies published since 2000
[1]. However, the majority of the data included in this paper came from antenatal testing, so it
may not be representative of the overall Indigenous population.
It is encouraging that we document a significant reduction in HBsAg positivity over time in
Indigenous individuals tested for HBV from 803% in the pre-vaccine era to 177% in the post
1990 period. However, it is important to note that the prevalence of HBsAg was falling prior to
the introduction of universal vaccination with the rate of decline not significantly different in
the post-intervention period. A data linkage study examining HBV seroprevalence in birthing
mothers in the NT before and after the introduction of universal vaccination, reported HBV
prevalence in Indigenous women falling from 35% in the pre-vaccine era to 08% in those
born after 1989 [10]. Equivalent figures from our data are approximately double these esti-
mates; this is attributable to our finding that Indigenous men have an OR of chronic HBV
infection of 153 compared to Indigenous women. This disparity in HBsAg positivity between
men and women has also been documented in other HBV-endemic regions of the world
[18,19] and cautions against using antenatal data as a tool for assessing changes in chronic
HBV infection prevalence over time. The Liu study [10] also suggests that chronic HBV infec-
tion prevalence was falling, albeit at a slower rate (reduction per year 008%) prior to universal
vaccination.
There are several potential explanations for the decline in HBsAg positivity prior to the
introduction of universal HBV vaccination. In the NT Indigenous population the exclusive
HBV genotype identified to date is HBV/C4 [11]. Genotype C HBV-infected individuals
undergo HBeAg sero-conversion at least a decade later than other genotypes [20]. Women of
childbearing age with genotype C HBV typically remain HBeAg positive and have very high
viral loads at the time they give birth, hence facilitating vertical transmission [21]. It is possible
that changes in birthing practices over time, moving from community to hospital births (from
the mid-1970s), may have contributed to this decline [22]. Cultural practices in general and
specifically ‘men’s business’ (e.g. traditional circumcision, scarification, and bloodletting) have
changed over time to potentially include less blood exposures [23,24]. The introduction of sin-
gle use needles, syringes, and medication vials within public healthcare systems in the mid
1980’s and 1990’s respectively may have also contributed.
Chronic hepatitis B in Australia’s northern territory
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In non-Indigenous individuals HBsAg positivity actually increased post-1990. It is likely
that this increase represents individuals who were not born in the NT and migrated from high
prevalence countries, particularly China and South East Asia. The lack of country of birth data
for the non-Indigenous people limits the ability to explore this group, however published evi-
dence would suggest that at least half those with chronic HBV infection in the NT were born
overseas [9]. Australian Bureau of Statistics 2011 census data show the absolute number of
people in the NT from the Philippines and Cambodia doubled between 1996 and 2011, while
those born in China, and India tripled [25]. We know from international data that migrants
born overseas and now living in high-income countries, retain a chronic HBV infection preva-
lence that mirrors that of their birth country and that half are non-immune to HBV and would
benefit from vaccination [26]. Obviously Australia’s universal childhood vaccination program
will have no impact in this group and alternative screening and vaccination strategies need to
be considered.
We report the first detailed data for the NT and for Indigenous Australians regarding anti-
HBs and anti-HBc positivity, documenting high levels of anti-HBc positivity in Indigenous
Australians: an overall prevalence of 38%, and > 50% in those born prior to 1950. These levels
of anti-HBc positivity are similar to those reported from China prior to the introduction of
their HBV vaccination program [27]. We also report a steady decrease in anti-HBc positivity
over time in both Indigenous and non-Indigenous Australians, which predates the introduc-
tion of universal vaccination. However, anti-HBc positivity, representing natural infection, is
still over 10% in the post-1990 birth cohort. We have previously described the molecular virol-
ogy of HBV/C4 in detail [11], showing that it is a recombinant virus with a different serotype
to the vaccine strain (ayw3 as opposed to adw2); this is a potential virological explanation for
suboptimal vaccine efficacy.
Twenty year follow up data from The Gambia (also a region with a serotype mismatch)
reports HBsAg positivity, in their cohort who were fully vaccinated at birth, as 08% and anti-
HBc positivity as 274% [28]. This is similar to our data suggesting good protection from the
vaccine program against chronic infection but only partial protection against having ever had
natural infection. In contrast, data from Alaska, showed that in a vaccinated cohort followed
up 22 years after initial vaccination zero individuals were HBsAg positive and only 1% of the
cohort were anti-HBc positive [29].
The key limitation of this study is the use of testing data as opposed to a prospective sero-
survey design. This methodology was guided by the wishes of NT Indigenous people to make
the best use of existing data prior to asking for more blood samples, which as well as being cul-
turally appropriate, had the additional benefit of being a low-cost approach. Although our
denominator population was those referred for HBV serology, we believe it is representative of
the NT population in general for the Indigenous population, where testing is largely driven by
screening rather than clinical indication. In addition to antenatal screening, all Indigenous res-
idents of the NT aged 15–55 years are offered an annual adult health check including HBV
serology. Coverage of the Indigenous specific adult health check in the NT for 2011 was 20%
[30] of the target population and we have serology results for> 20% of the NT Indigenous
population in this age group. During the study time period there was minimal uptake of HBV
antiviral therapy and HIV/HBV co-infection is rare [31]. Therefore at a population level there
is unlikely to be an impact due to antiviral therapies on the results.”
Our data show the proportion of women tested in the childbearing years is greater than
men, but that this difference is greater for non-Indigenous people. This suggests less true
screening in the non-Indigenous group outside of antenatal testing and a greater role for clini-
cally indicated testing. This may have led to an over-estimation of HBsAg positivity in non-
Indigenous NT residents, particularly males. Our dataset lacks numbers in the very old and
Chronic hepatitis B in Australia’s northern territory
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very young age groups, particularly for those born since the introduction of universal vaccina-
tion in 1990. It is likely that the potential referral bias will be most evident in these younger
groups where there are small numbers. We do therefore caution against over-interpretation of
the most recent data due to the relatively small numbers of tests carried out overall in the most
recent birth cohorts (1990 onwards) and attendant wide confidence intervals around point
estimates, particularly in the non-Indigenous group.
Furthermore, we may have over-estimated chronic HBV infection prevalence overall as we
have assumed all HBsAg positive individuals have chronic HBV infection when some will rep-
resent acute HBV. We feel that this is a reasonable assumption based on our sensitivity analysis
and the low rates of acute HBV in the NT (27 acute HBV notifications between 2007–2011
[13]), equating to an absolute change of 017% on the overall HBsAg positivity rate of 34%.
In conclusion we report HBsAg prevalence in Indigenous Australians in the NT is falling
but remains greater than 6%. Our data support the assertion that the HBV vaccination pro-
gram is associated with a decreasing burden of chronic HBV infection; however they also sug-
gest that the vaccine is only one factor responsible for this reduction in the NT. Our data
identify an urgent need for systematic studies examining markers of HBV prevalence in people
born after 1990 to enable a comprehensive analysis of the effectiveness of universal vaccination
as an intervention. Our findings have implications not only for the planning and delivery of a
sustainable public health response to chronic HBV infection in the NT, but for Indigenous
people more widely. In addition, they have implications for other populations where a mis-
match exists between currently used hepatitis B vaccines and dominant circulating HBV sero-
types. The described low cost culturally acceptable model of providing contemporary
surveillance data could be adapted to other Indigenous populations.
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